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Abstract
The sensing of pathogen infection and subsequent triggering of innate immunity are key to controlling zoonotic infections.
Myxoma virus (MV) is a cytoplasmic DNA poxvirus that in nature infects only rabbits. Our previous studies have shown that
MV infection of primary mouse cells is restricted by virus-induced type I interferon (IFN). However, little is known about the
innate sensor(s) involved in activating signaling pathways leading to cellular defense responses in primary human immune
cells. Here, we show that the complete restriction of MV infection in the primary human fibroblasts requires both tumor
necrosis factor (TNF) and type I IFN. We also demonstrate that MV infection of primary human macrophages (pHMs)
activates the cytoplasmic RNA sensor called retinoic acid inducible gene I (RIG-I), which coordinately induces the production
of both TNF and type I IFN. Of note, RIG-I sensing of MV infection in pHMs initiates a sustained TNF induction through the
sequential involvement of the downstream IFN-regulatory factors 3 and 7 (IRF3 and IRF7). Thus, RIG-I-mediated co-induction
of TNF and type I IFN by virus-infected pHMs represents a novel innate defense mechanism to restrict viral infection in
human cells. These results also reveal a new regulatory mechanism for TNF induction following viral infection.
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Introduction
Myxoma virus (MV), a member of the poxvirus family, is a large
cytoplasmic DNA virus that infects only rabbits [1,2]. No other
vertebrate species outside of lagomorphs, including humans, have
ever been reported to contract a productive MV infection. This
strict host specificity of MV provides an important avenue to study
how cross-species virus infections can be manipulated, and how
zoonotic infections might be regulated in humans. For instance,
the mitogen-activated protein kinase (MAPK) Erk1/2-type I
interferon (IFN-a/b)-STAT1 signaling cascade has been revealed
as the principal antiviral defense pathway which restricts MV
infection in primary mouse embryo fibroblasts. In fact, disruption
of the STAT1 signaling cascade renders normally resistant mice
highly susceptible to lethal MV infection [3]. These observations
demonstrate the importance of defining the functional antiviral
mechanisms in primary cells, as compared to transformed or
immortalized cell lines [4]. Little is known, however, about the
innate defense pathways that inhibit MV infection in normal
primary human cells.
Innate cellular defenses can be triggered by a variety of
mechanisms, including host recognition of pathogen-associated
molecular patterns (PAMPs) through pattern recognition recep-
tors, such as Toll-like receptors (TLRs) and cytoplasmic nucleic
acid sensors [5,6]. Although TLR3, TLR7, TLR8 and TLR9 are
known to recognize certain viral nucleic acids, these TLRs are
exclusively localized in the endosomal compartments and
therefore might be unable to sense cytoplasmic viral PAMPs [7].
Cellular surveillance of invading DNA viruses likely involves
multiple viral PAMPs, particularly certain atypical RNAs. For
example, many DNA viruses produce dsRNA and/or 59-
triphosphate RNA, as viral by-products, during their replicative
life cycles [5,8,9]. Both viral dsRNA and 59-triphosphate RNA can
potently activate the cytoplasmic RNA sensor called retinoic acid
inducible gene I (RIG-I) [9–12]. In contrast, certain other viral
RNA moities are specifically detected by another cytoplasmic
RNA sensor called melanoma differentiation-associated gene 5
(MDA5) [13]. Thus, it is highly plausible that infecting DNA
viruses may generate various ‘‘accidental’’ RNA ligands which
engage cytoplasmic RNA sensors. Current reported studies are
focusing predominantly on the roles of RIG-I and MDA5 in
triggering innate defenses against RNA viruses [13,14]. Conse-
quently, it remains to be determined how critical RIG-I and
MDA5 might be in sensing DNA viruses.
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evolutionarily conserved signaling pathways, such as NF-kB and
the IFN-regulatory factors 3 and 7 (IRF3 and IRF7) [15].
Activation of these pathways often culminates in the induction of
an array of antiviral cytokines, including type I IFN and tumor
necrosis factor (TNF), which are widely considered crucial
components of innate antiviral immunity [16–18]. However,
although the signaling cascades linking RIG-I and MDA5 sensing
to IFN-a/b induction have been extensively characterized
[5,9,19], so far little is known as to how RIG-I and/or MDA5
signaling may be linked with TNF expression.
Here, we show that MV is permissive in cultured primary
human fibroblasts and that potent restriction of MV infection in
primary human fibroblasts requires TNF in conjunction with type
I IFN. In contrast, MV infection of primary human macrophages
(pHMs) triggers induction of both TNF and type I IFN that
prevents permissive infection. Furthermore, we show that MV
infection of pHMs is sensed largely by RIG-I, and the subsequent
TNF induction is mediated through the sequential involvement of
IRF3 and IRF7. Our results demonstrate that RIG-I-mediated co-
induction of TNF and IFN is a novel innate defense mechanism
that restricts MV proliferation in normal primary human cells and
reveals a hitherto unrecognized regulatory pathway for TNF
induction in virus-infected cells.
Results
TNF and type I IFN are required for complete restriction
of MV infection in primary human fibroblasts
The potent oncolytic ability of MV in treating human tumors in
mouse xenograft models [20–22] prompted our interest in
studying MV infectivity in normal primary human cells.
Therefore, we initially infected CCD-922Sk primary human skin
fibroblasts with a MV construct expressing b-galactosidase (b-gal)
under the control of a late viral promoter. Following low
multiplicity of infection, X-gal staining revealed that, in contrast
to the nonpermissive phenotype in MV-infected primary murine
cells [3], MV formed classic productive blue foci (Figure 1A),
indicating that CCD-922Sk fibroblasts were permissive for MV
infection. Similar results were obtained with a variety of other
primary human fibroblasts tested in this fashion (data not shown).
Next, we infected CCD-922Sk fibroblasts with MV in the
presence of exogenous human IFN-b as a prototypic representa-
tive of type I IFN to ascertain whether this cytokine could reverse
the permissive phenotype [18,23]. As shown in Figure 1B,
exogenous IFN-b reduced MV yield by approximately one log.
To characterize other potential host factors that might also inhibit
MV infection in human fibroblasts, we then investigated the
potential anti-MV effects of other antiviral cytokines. For example,
TNF has been shown to possess antiviral activities under certain
circumstances, particularly in collaboration with type I IFN [24].
To this end, we infected CCD-922Sk fibroblasts with MV in the
presence of TNF alone, or together with IFN-b. We observed that
approximately one log reduction in MV yield was obtained with
TNF treatment alone (Figure 1B). Interestingly, this anti-MV
effect of either cytokine alone was considerably enhanced when
the two cytokines were combined, as that treatment inhibited MV
replication by more than 4-log (Figure 1B). To further validate the
anti-MV properties of TNF, we then constructed a recombinant
MV that constitutively expresses human TNF (MV-hTNF, Figure
S1). Compared with the control MV, MV-hTNF yield was
approximately a log lower in CCD-922Sk fibroblasts (Figure 1C).
Of note, this reduction could be reversed by a TNF neutralizing
antibody (data not shown). Significantly, the replication of MV-
hTNF was now nearly abolished by IFN-b alone (Figure 1C). We
further observed that, although the relative anti-MV potencies of
TNF and type I IFN varied between individual infections, TNF in
combination with either IFN-b or IFN-aA uniformly restricted
MV replication in all primary human cells tested (data not shown).
Taken in aggregate, these data demonstrate that TNF synergizes
with type I IFN to achieve potent innate restriction of MV
replication in primary human fibroblasts.
To further characterize the antiviral potencies of IFN-b and
TNF in CCD-922Sk fibroblasts, we then infected the cells with
encephalomyocarditis virus (EMCV), an RNA virus from the
picornaviridae family, in the presence of IFN-b or TNF. Unlike
MV, EMCV yield could be inhibited by more than 5-log in CCD-
922Sk fibroblasts by IFN-b alone (Figure 1D). However, TNF
alone exhibited no anti-EMCV efficacy (Figure 1D), nor did it
affect IFN-b inhibition of EMCV (data not shown). Together,
these results indicate that, at least in human fibroblasts, whether
TNF is needed to synergize with type I IFN to achieve the full
antiviral state depends significantly upon the infecting virus.
MV infection elicits robust induction of TNF and type I
IFN in primary human macrophages
The involvement of TNF and type I IFN in restricting MV
infection prompted us to explore macrophages as a model system
to investigate the cytokine inducibility by MV infection because
macrophages are generally considered as particularly potent TNF
producers in response to a variety of stimuli [25]. To this end, we
infected monocyte-derived pHMs with MV and then measured
TNF production in response to the viral infection. A significant
increase in secreted TNF protein was detected in the media of
MV-infected pHMs, but not in the media of MV-infected CCD-
922Sk fibroblasts or primary human lymphocytes (Figure 2A).
Because type I IFN was shown to potentiate the anti-MV effects of
TNF (Figures 1B and C), we therefore examined whether MV
infection could also induce type I IFN expression. In accord with
TNF production, IFN-b was only detected in the media of MV-
infected pHMs (Figure 2B). Next, we examined MV b-gal activity
driven by a late viral promoter following MV infection in pHMs as
an indicator for MV DNA replication status. As shown in
Author Summary
Myxoma virus, a member of the cytoplasmic DNA poxvirus
family, causes a lethal disease called myxomatosis in the
European rabbit. It has been known for over a half-century
that other vertebrates, including humans, are highly
resistant to myxoma virus infection, even following direct
injections of live myxoma virus. Interestingly, myxoma
virus has been recently shown to potently infect and kill
malignant human tumors xenografted in mice. However,
little is known about how normal human immune cells
sense and suppress myxoma virus multiplication at the
cellular level. Here, we show that the cytoplasmic RNA
helicase RIG-I is the major sensor that detects invading
myxoma virus in primary human macrophages and
triggers the co-induction of both tumor necrosis factor
and type I interferon. Together, tumor necrosis factor and
type I interferon inhibit myxoma virus in otherwise
permissive cells, such as human fibroblasts. Conceptually,
our study thus demonstrates that intracellular RNA sensors
may, in general, play a more important role than
previously thought in the innate antiviral responses
against DNA virus infections in human cells.
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in pHMs but this level could be increased with neutralizing
antibody to either TNF or type I IFN alone, and further elevated
by adding the two antibodies together. In total, these results
indicate that MV-infected pHMs are restrictive because of the
secreted TNF and type I IFN induced as a response to MV
infection.
Although TNF synthesis and secretion is regulated at multiple
levels, the transcriptional upregulation of TNF gene expression is a
critical point of control over TNF production [26]. Therefore, we
used RT-PCR to determine whether MV infection elicited the
enhanced expression of TNF mRNA in pHMs. Consistent with
the TNF protein data, MV infection resulted in a substantial
increase in both TNF and IFN-b mRNA, with similar kinetics
(Figure 2D). No appreciable amounts of TNF or IFN-b mRNAs
were detected in either MV-infected CCD-922Sk fibroblasts or
primary human lymphocytes (data not shown). Collectively, these
results indicate that the co-induction of TNF and IFN-b secretion
from MV-infected pHMs was regulated through augmented
mRNA transcription of each cytokine.
Next, to determine whether MV replication was required to
induce TNF or type I IFN expression in pHMs, we prepared UV-
inactivated MV that was no longer able to synthesize significant
levels of functional viral RNA or protein in a fashion similar to that
Figure 1. TNF and IFN-b are required for potent restriction of MV infection in primary human fibroblasts. (A) Primary human skin
fibroblasts CCD-922Sk were mock-infected or infected with MV. X-gal staining was performed to visualize blue MV foci 48 h after infection. (B) CCD-
922Sk fibroblasts were infected with MV in the absence or presence of TNF or IFN-b alone or TNF plus IFN-b. MV yields were determined by the
standard plaque assay using BGMK cells at 48 h after infection. (C) CCD-922Sk fibroblasts were infected with the control MV (constructed with the
same vector but no human TNF gene) or the recombinant MV expressing human TNF (MV-hTNF) in the absence or presence of IFN-b. The viral yields
of both control MV and MV-hTNF were determined by the standard plaque assay using RK-13 cells at 48 h after infection. (D) CCD-922Sk fibroblasts
were infected with EMCV in the absence or presence of IFN-b or TNF. EMCV quantities were titrated by the standard plaque assay using BHK cells at
48 h after infection. Data in (B), (C) and (D) represent mean +/2 SD.
doi:10.1371/journal.ppat.1000099.g001
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that the UV-inactivated MV particles retained the ability to enter
into the cell interior (data not shown). As demonstrated in
Figure 2D, UV-inactivated MV was unable to upregulate mRNA
expression of either TNF (3rd panel) or IFN-b (4th panel) in
pHMs. Together, these data suggest that the de novo synthesis of
MV macromolecules is critical for triggering the cellular signaling
cascades leading to TNF and IFN-b induction in pHMs.
RIG-I mediates MV-elicited induction of TNF and type I
IFN in primary human macrophages
Like all poxviruses, MV synthesizes its viral DNA, RNA and
protein in the cytoplasm of infected cells [2]. Thus, the finding that
MV-elicited TNF and IFN-b mRNA induction in pHMs required
active MV infection (Figure 2D) led us to postulate that
cytoplasmic sensors, such as RIG-I or MDA5 [12,13], might
sense cytoplasmic nucleic acid intermediates derived from MV
replication. To test this hypothesis, we examined the basal levels of
RIG-I and MDA5 in pHMs. As revealed by RT-PCR, mRNAs for
the nucleic acid sensors RIG-I and MDA5 were constitutively
expressed in pHMs (Figure 3A). Next, to investigate whether these
sensors were involved in MV-elicited TNF or IFN induction, we
employed siRNAs to individually suppress the expression of RIG-I
and MDA5 in pHMs, as previous reports have shown that siRNA
transfection could efficiently inhibit a variety of target genes in
primary macrophages [28,29]. We observed that transfection of
RIG-I siRNA-1 and MDA5 siRNA significantly knocked down the
mRNA expression of RIG-I (Figure 3A, top) and MDA5
(Figure 3A, middle). We then conducted MV infections in the
pHMs in which the expression of RIG-I and MDA5 mRNA had
been respectively silenced. As shown in Figure 3B, MDA5 mRNA
suppression reduced MV-elicited TNF production only by
approximately 30%, whereas RIG-I mRNA knockdown inhibited
TNF induction by 85% in MV-infected pHMs (Figure 3B).
Figure 2. Primary human macrophages produce TNF and IFN-b in response to MV infection. (A, B) Primary human macrophages (pHMs),
CCD-922Sk fibroblasts and primary human lymphocytes were mock-infected or infected with MV. TNF (A) and IFN-b (B) accumulation in the culture
supernatants was assessed by ELISA 24 h post-infection. (C) pHMs were mock-infected or infected with MV in the absence or presence of TNF
neutralizing antibody (Ab) or IFN-a/b neutralizing Ab alone or TNF Ab plus IFN-a/b Ab as specified. MV b-gal activity was determined by measuring
absorbance at 420 nm and normalized to the total cellular protein levels at 48 h after infection. (D) pHMs were infected with MV or UV-inactivated
MV for various times (below lanes) and total RNA was analyzed by RT-PCR for induction of TNF and IFN-b mRNA. GAPDH was used as control. Data in
(A), (B) and (C) represent mean +/2 SD.
doi:10.1371/journal.ppat.1000099.g002
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infected pHMs (Figure 2), we then examined whether MV-elicited
IFN-b expression was also mediated by RIG-I. As demonstrated in
Figure 3C, RIG-I silencing reduced IFN-b production comparably
to that of TNF. Importantly, virus yield analysis further revealed
that RIG-I knockdown increased MV progeny production by 30-
fold (Figure 3D) and augmented MV-derived b-gal activity by
80% (data not shown). Taken together, these data suggest that
RIG-I is a major common mediator for MV-elicited induction of
TNF and type I IFN in infected pHMs and that knockdown of
RIG-I reduces this co-induction and thereby renders pHMs
permissive for MV infection.
To verify the specificity of RIG-I siRNA silencing, we employed
an additional RIG-I siRNA designated RIG-I siRNA-2. As shown
in Figure S2A, RIG-I siRNA-2 displayed a silencing potency
indistinguishable from that of RIG-I siRNA-1. Phenotypically,
RIG-I silencing by RIG-I siRNA-2 reduced the MV-induced
expressions of both TNF and IFN-b to the similar levels as seen
with RIG-I siRNA-1 (Figures S2B and S2C). Because the
sequences of RIG-I siRNA-1 and RIG-I siRNA-2 are different,
it is thus unlikely that these siRNA oligos both knockdown a
common off-target gene that is responsible for MV-elicited
expression of TNF and type I IFN. Moreover, we also observed
that RIG-I siRNAs used here themselves did not trigger undesired
type I IFN response in pHMs (Figures S3A and S3B) [30,31].
Next, to examine for any potential role of TLRs in MV-infected
pHMs, we silenced the expressions of TLR4, MyD88 and Trif
using specific siRNAs. These were chosen because all known
TLRs use either the adaptor MyD88 or Trif to transduce signals,
except for TLR4, which uses both adaptors MyD88 and Trif [7].
We observed that inhibition of TLR signaling with any of these
siRNAs had no influence on either TNF or type I IFN production
in MV-infected pHMs (data not shown).
IRF3 is essential for RIG-I-mediated induction of TNF and
type I IFN in primary human macrophages
Upon ligand engagement, RIG-I recruits the adaptor protein
MAVS [32], also known as VISA, IPS-1 or Cardif [33–35],
Figure 3. MV-elicited production of TNF and IFN-b is mediated by RIG-I in primary human macrophages. (A) pHMs were transfected
with control siRNA or siRNAs targeting cytoplasmic RNA sensors RIG-I (top panel) or MDA5 (middle panel). The cells were analyzed 48 h later by RT-
PCR for the indicated mRNA levels. GAPDH was used as control. (B, C) RIG-I is critically required for MV-elicited production of both TNF (B) and IFN-b
(C) in pHMs. pHMs or various siRNA pHMs were mock-infected or infected with MV and the accumulation of TNF and IFN-b in the culture
supernatants was assessed by ELISA 24 h post-infection. (D) RIG-I mediates cellular restriction to MV infection in pHMs. pHMs or control siRNA or RIG-I
siRNA pHMs as indicated were infected with MV. MV yields were determined by the standard plaque assay using BGMK cells at 48 h after infection.
Data in (B), (C) and (D) represent mean +/2 SD.
doi:10.1371/journal.ppat.1000099.g003
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IRF3, a central transcription factor for IFN-a/b expression
[36,37]. Importantly, recent studies demonstrate that IRF3 is also
important for TNF expression [38–41]. To investigate whether
signaling from MAVS to IRF3 is critically involved in RIG-I-
mediated induction of TNF or type I IFN following MV infection,
we first silenced MAVS expression in pHMs using MAVS siRNA
(Figure 4A). We then prepared pHM nuclear extracts and
examined, by immunoblotting, IRF3 nuclear translocation with
or without MAVS silencing in comparison with RIG-I silencing.
As revealed in Figure 4B (top panel), MV infection robustly
induced IRF3 nuclear translocation [36]. This nuclear mobiliza-
tion of IRF3 was strongly inhibited by knockdown of either RIG-I
(Figure 4B, 2nd panel) or MAVS (Figure 4B, 3rd panel).
Immunofluorescent staining revealed a similar distribution trend
for IRF3 following MV infection (Figure 4C). Together, these
results show that MV-induced IRF3 activation is dependent on the
functional integrity of upstream signaling of both RIG-I and
MAVS.
To investigate the physiological significance of MV-induced
IRF3 activation in pHMs, we employed IRF3 siRNA to
specifically knock down IRF3 expression (Figure 4D). This
knockdown of IRF3 substantially reduced TNF protein secretion
in the supernatant of MV-infected pHMs (Figure 4E). Similarly,
MAVS silencing also strongly inhibited MV-elicited TNF
production in pHMs (Figure 4E). These results suggest that
MAVS-IRF3 signaling is important for TNF production in MV-
infected pHMs. Consistent with these TNF protein data, we also
observed that induction of MV-elicited TNF and IFN-b mRNA
were both inhibited by IRF3 silencing (Figure 4F and data not
shown), thus indicating that IRF3 regulates TNF and IFN-b
production mainly through transcriptional activation. Taken
together, our findings suggest that the RIG-I-MAVS-IRF3
signaling axis, a canonical cascade that is involved in IFN-a/b
induction following RNA virus infections, can also be exploited in
pHMs to co-transmit TNF-inducing signals emanating from a
cytoplasmic DNA virus infection.
IRF7 is required for sustaining RIG-I-mediated TNF
induction in primary human macrophages
IRF7 shares considerable structural and functional similarities
with IRF3 [36,42]; therefore, we investigated whether IRF7 also
played a role in RIG-I-mediated TNF induction in MV-infected
pHMs. To this end, we first analyzed IRF7 protein levels in MV-
infected pHMs by immunoblotting. We found that IRF7 protein
was not detectable in uninfected pHMs, but was significantly
induced by MV infection (Figure 5A). Notably, MV-induced IRF7
expression in pHMs became markedly augmented at 12–16 h
after infection and remained elevated even at 24 h post-infection.
To determine whether IRF7 was involved in RIG-I-mediated
TNF induction, we silenced MV-induced expression of IRF7 in
pHMs using IRF7 siRNA (Figure 5A, middle panel). Next, we
measured TNF secretion in the media of control and IRF7-
silenced pHMs at 24 h after MV infection. IRF7 silencing reduced
MV-elicited TNF production, but to a lesser degree than with
IRF3 silencing (Figure 5B). Subsequently, we compared the
kinetics of MV-elicited TNF production in pHMs. Initially, the
amounts of TNF protein secreted by control and IRF7-silenced
pHMs were similar during the first 12 h of MV infection.
However, further increases in TNF protein were significantly
impaired in IRF7-silenced pHMs at later time points (Figure 5C).
In order to ascertain whether IRF7 affected MV-elicited TNF
induction at the transcriptional or post-transcriptional level, we
analyzed TNF mRNA in both control and IRF7-silenced pHMs
after various times of MV infection. As revealed by RT-PCR,
TNF mRNA was induced to similar levels in both groups at the
early times (8–12 h) (Figure 5D). In contrast, much less TNF
mRNA was detected at the later times in IRF7-silenced pHMs
after MV infection (Figure 5D). These results are congruent with
the TNF protein data (Figure 5C) and suggest that IRF3 is
responsible for the initial triggering of TNF induction while IRF7
impacts the secondary amplification of TNF expression by
sustaining TNF gene transcription in MV-infected pHMs.
The prominent role of IRF7 in sustaining MV-elicited later
stage TNF production piqued our interest in the primary
regulatory pathway involved in MV-induced IRF7 expression.
In this regard, previous work shows that virus-activated IRF3 and
IRF7 can bind to the IFN-stimulated response element (ISRE) and
IRF-binding element (IRFE) in the endogenous IRF7 promoter to
initiate IRF7 transcription [43]. Therefore, we performed a
chromatin immunoprecipitation (ChIP) assay to determine
whether MV infection of pHMs induced IRF3 and IRF7 binding
to the IRF7 ISRE and IRFE at 12 h after infection, as IRF7 first
became markedly upregulated at this time point (Figure 5A, top
panel). We observed that the PCR-amplified DNA bands
diagnostic for the ISRE and IRFE elements in the endogenous
IRF7 promoter were detected in the anti-IRF3 (Figure 6A, top
panel) and anti-IRF7 (Figure 6B, top panel) antibody immuno-
precipitates of MV-infected pHMs, but not in the control antibody
immunoprecipitates. Because TNF-NF-kB and IFN-STAT1
pathways are known to activate the IRF7 gene [36,44,45], we
silenced the expression of NF-kB p65 (Figure 6C, left) and STAT1
(Figure 6C, right) to ascertain whether these signaling cascades
had any impact on the observed IRF3 and IRF7 binding. Notably,
the specific DNA bands were unaffected by silencing of NF-kB
p65 (Figures 6A and B, 5th panels) or STAT1 (Figures 6A and B,
6th panels). In particular, STAT1 forms a heterotrimeric complex
called ISGF3 (IFN-stimulated gene factor 3) with STAT2 and
IRF9 following the activation by type I IFN and is a major
stimulator for IRF7 gene expression [36]. Thus, to further define
the STAT1 silencing effects, we observed that no positive ChIP
signals were detected for IRF7 gene promoter in STAT1 siRNA
pHMs following IFN-aA treatment (data not shown). These results
together indicate that NF-kB p65 and STAT1 are not involved in
MV-induced direct binding of IRF3 and IRF7 to the endogenous
IRF7 promoter. Significantly, no specific DNA bands diagnostic
for the IRF7 ISRE/IRFE promoter elements were detectable
when the expression of RIG-I (Figures 6A and B, 2nd panels) or
MAVS (Figures 6A and B, 4th panels) was knocked down as
shown in Figure 3A and Figure 4A, respectively. In contrast, when
MDA5 was silenced as shown in Figure 3A, ChIP retained the
positive signals (Figures 6A and B, 3rd panels). This result is
congruent with the findings that MDA5 silencing itself had little
inhibitory impact on MV-induced activation of IRF3 and IRF7
(data not shown). Taken collectively, these data suggest that both
IRF3 and IRF7 are directly involved in promoting MV-triggered
IRF7 gene transcription through RIG-I and MAVS, but
independently of type I IFN and NF-kB signaling.
Discussion
Deciphering the cellular sensing mechanisms involved in virus-
elicited TNF or IFN induction is key for understanding the biology
of these cytokines in innate antiviral defenses. In this study, we
show that MV infection of pHMs triggers the cytoplasmic RNA
sensor RIG-I, which activates a MAVS-IRF3/IRF7 cascade
leading to the co-induction of TNF and type I IFN. Although
IRF3 has been shown to mediate TNF induction under various
RIG-I Mediates MV-Induced TNF/IFN
PLoS Pathogens | www.plospathogens.org 6 July 2008 | Volume 4 | Issue 7 | e1000099Figure 4. IRF3 is critical for triggering MV-elicited TNF induction in primary human macrophages. (A) pHMs were transfected with
control siRNA or MAVS siRNA. The cells were analyzed 48 h later by RT-PCR for the indicated mRNA levels. GAPDH was used as the control. (B) Control
siRNA pHMs or RIG-I siRNA or MAVS siRNA pHMs as indicated were infected with MV for various times (below lanes) and the nuclear extracts were
probed for nuclear IRF3 (nuc-IRF3). Nuclear USF2 (nuc-USF2) was used as nuclear protein loading control. (C) Control siRNA pHMs or RIG-I siRNA or
MAVS siRNA pHMs as indicated were infected with MV for 0 h or 10 h and were immunofluorescence-stained for IRF3 (red). Nuclear DNA was
counterstained with DAPI (blue). Bars are 10 mm. (D) pHMs were transfected with control siRNA or IRF3 siRNA as indicated and were analyzed 72 h
later by immunoblotting for IRF3 protein levels. b-actin was used as control. (E) pHMs or various siRNA pHMs as indicated were infected with MV for
24 h and TNF protein in the culture supernatants was assessed by ELISA. Data represent mean +/2 SD. (F) Control siRNA pHMs or IRF3 siRNA pHMs
were infected with MV for various times (below lanes) and the cells were analyzed by RT-PCR for the indicated TNF mRNA levels. GAPDH was used as
control.
doi:10.1371/journal.ppat.1000099.g004
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viral infections [38–41], the collaboration between IRF3 and IRF7
resulting in sustained TNF induction has not been recognized
before. Thus, our study has revealed novel insights into the
signaling control of TNF production, and its close linkage with
type I IFN upregulations in virus-infected human macrophages.
The first indication of potential involvement of the cytoplasmic
RNA helicases in sensing DNA virus infection came from the
Figure 5. IRF7 is crucial for sustaining MV-elicited TNF induction in primary human macrophages. (A) Control siRNA pHMs or IRF7 siRNA
pHMs were infected with MV for various times (below lanes) and the whole cell lysates were analyzed for MV-induced expression of IRF7 protein. b-
actin was used as control. (B) pHMs or various siRNA pHMs were mock-infected or infected with MV. TNF protein in the culture supernatants was
assessed by ELISA 24 h post-infection. (C) IRF7 expression and TNF production kinetics. Control siRNA pHMs or IRF7 siRNA pHMs were infected with
MV for various times as indicated and TNF protein in the culture supernatants was assessed by ELISA. (D) IRF7 is required for sustaining TNF gene
transcription activated by MV infection. Control siRNA pHMs or IRF7 siRNA pHMs were infected with MV for various times (below lanes) and the cells
were analyzed by RT-PCR for the indicated TNF mRNA levels. GAPDH was used as control. Data in (B) and (C) represent mean +/2 SD.
doi:10.1371/journal.ppat.1000099.g005
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for RIG-I and MDA5 signaling, in which IFN-b induction was
shown to be substantially reduced in MAVS-deficient mouse
embryo fibroblasts following the infection by modified vaccinia
Ankara [46]. More recently, DNA viruses herpes simplex virus-1
and adenovirus were shown to replicate to much higher titers in
RIG-I mutant human hepatoma cells Huh-7.5.1. than in the
parental Huh-7 cells [47]. The critical function of RIG-I in sensing
MV infection of pHMs raises an interesting question about why
MDA5 has an apparently less significant role in triggering MV-
elicited induction of TNF and IFN-b. Although RIG-I and MDA5
belong to the same family of DexD/H box helicases [9], MDA5 is
known to preferentially recognize picornaviruses and poly(I:C)
[13]. Thus far, MDA5 deficiency has been shown to have either
no effect, or only a slight inhibitory impact, on the type I IFN
responses elicited by other RNA and DNA viruses [48]. Taken
together with these previous studies, our data thus point to an
emerging theme that RIG-I may play a more general role in
innate recognition of various DNA viruses.
This is of importance considering the fact that information
remains limited about the cytoplasmic DNA sensor(s). Presently,
the only characterized cytoplasmic DNA sensor DAI, also known
as DLM-1/ZBP1, was shown to mediate type I IFN induction
following infection with herpes simplex virus-1 in L929 cells [49].
However, sensing of cytoplasmic DNA by DAI was found to be
dispensable in mouse embryo fibroblasts [50]. Thus, it appears
that the role of DAI in DNA sensing may be a cell type specific or
functional status-related phenomenon. In the present study, we
observed that DAI knockdown inflicted only a minor inhibitory
effect on TNF and IFN-b induction in MV-infected pHMs (data
not shown). This result seems to further emphasize the importance
of RIG-I as an innate sensor for DNA virus infections.
Our previous study of MV tropism restriction showed that MV
infection not only induced type I IFN in primary mouse embryo
fibroblasts but MV replication was exquisitely sensitive to the
induced IFN, demonstrating that the type I IFN response is a
predominant tropism determinant for MV in mouse fibroblasts
[3]. Of note, a previous study using primary human neonatal
foreskin fibroblasts reported that the early passage (P1–3)
fibroblasts were permissive for MV infection, while late passage
cells (P5–10) became resistant at a time that paralleled the
acquisition of constitutive IFN-b secretion, thus indicating a major
role for type I IFN in inhibiting MV infection in those cells [51]. In
the present study, however, we found that adult breast skin
Figure 6. MV induces IRF3 and IRF7 binding to the endogenous IRF7 promoter in primary human macrophages. (A, B) Chromatin
immunoprecipitation assay. IRF3 and IRF7 binding to the ISRE and IRFE in the endogenous IRF7 promoter was determined in control siRNA pHMs or
various siRNA pHMs as indicated after MV infection for 12 h using PCR to detect IRF7 ISRE and IRFE in immunoprecipitated chromatin fragments.
Lanes 1 and 2 are the PCR results for immunoprecipitated samples with the control antibody (Ab). Lanes 3 and 4 show PCR amplification of target
sequences in immunoprecipitated chromatin fragments with anti-IRF3 (A) or anti-IRF7 (B) antibody. Input represents PCR amplification of the total
input DNA in each sample from the corresponding treatment. (C) pHMs were transfected with control siRNA or specific siRNAs as indicated. The cells
were analyzed 72 h later by immunoblotting for protein levels of NF-kB p65 (left) and STAT1 (right). b-actin was used as control.
doi:10.1371/journal.ppat.1000099.g006
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conjunctival fibroblasts uniformly supported permissive MV
infection, regardless of the passage status, and all required both
TNF and type I IFN to fully inhibit MV proliferation (data not
shown). Taken together, these findings suggest that both TNF and
type I IFN are necessary for a full-fledged inhibition of MV
infection in a wide variety of the primary human fibroblasts tested
although type I IFN itself might still be able to act as a potent
inhibitor in certain cells.
We also report here that MV infection co-induced TNF and
type I IFN only in pHMs, but not in primary fibroblasts or
lymphocytes, in a RIG-I-dependent fashion. Hence, these data
imply either that certain MV gene products act as RIG-I signaling
pathway inhibitor(s) only in fibroblasts and lymphocytes or else
there exist unique signaling elements of the RIG-I pathway that
are restricted to pHMs. In either event, MV immunosubversion
effectors may well be inherently involved in the determination of
MV tropisms in primary human cells in a cell type-dependent
manner.
Although disruption of RIG-I signaling is conducive for MV
replication in pHMs, high titers of MV progeny are not achieved
because of premature death of MV-infected pHMs (data not
shown). This appears to lend support to an emerging notion that
the major function of pHMs in combating MV infection is to
provide an altruistic source of TNF and type I IFN. It has been
known for over a half-century that humans are highly resistant to
MV infection, even following direct injections of live MV [1], but
the molecular basis underlying the innate cellular restriction to
MV infection in humans has never been elucidated. Thus, this
novel RIG-I-coordinated signaling of TNF and type I IFN in
leukocytes such as pHMs would provide some clues to explain how
MV infection might be restricted in humans in vivo. In this regard,
future clinical trials of MV as a new oncolytic virus to treat human
cancers may provide a unique opportunity to determine the actual
physiological relevance of leukocyte-based TNF and type I IFN
responses in humans at the whole organism level.
Like IFN, TNF can also cause significant harm to the host when
over-expressed [52]. Thus, a tight controlover both TNF and type I
IFN induction and shut-off is a key to homeostasis. Here, we show
that IRF3 activationalone triggered only a transient upregulation of
TNF and type I IFN. In most cell types, IRF3 is constitutively
expressed, whereas IRF7 must usually be induced de novo [36,37].
Thus,thesequential involvementofIRF3and IRF7 intheearlyand
later phase of TNF production allows us to postulate that, if the
early phase production of TNF and type I IFN is sufficient to block
viral infection, then the later phase productionof both cytokines will
be coordinately curtailed. Taken collectively, sustaining TNF
induction through IRF3 and IRF7 thus provides the host with a
fine-tuned regulatory mechanism to allow for only needed TNF
expression in parallel with type I IFN. In particular, the
identification of IRF7 as a key regulator for sustained production
ofboth TNFand typeI IFNmayofferusefulcluesfordesigningnew
therapeutic strategies for disorders in which over-expression of
either cytokine is suspected as a major culprit.
Of relevance, recent work shows that in lipopolysaccharide-
stimulated mouse macrophages, TLR4 interacts initially with
MyD88 to mediate the early phase TNF expression and then with
the newly induced 4-1BBL to sustain longer term TNF production
[53]. Thus, sustained induction of TNF may be an intrinsic feature
that can take place through distinct signaling pathways in a
stimulus-specific fashion.
A pivotal step in sustaining the MV-elicited co-induction of
TNF and type I IFN in pHMs is the de novo synthesis of IRF7. Our
ChIP data reveal that MV-stimulated MAVS signaling caused the
direct binding of both IRF3 and IRF7 to the ISRE and IRFE sites
in the IRF7 promoter, and that this is unaffected by STAT1 or
NF-kB p65 knockdown. Notably, previous studies show that type I
IFN and TNF each potently stimulate IRF7 expression [36,44,45].
In this study, we observed that, in addition to TNF, MV infection
co-induced type I IFN in pHMs. We further observed that IRF7
was strongly induced in pHMs by either exogenous type I IFN or
TNF (data not shown), thus indicating that MV-elicited type I IFN
and TNF also likely contribute to IRF7 upregulation in pHMs.
Taken together, these data suggest that IFN-STAT1, TNF-NF-kB
and MAVS-IRF3/IRF7 signaling cascades are mobilized inde-
pendently following MV infection to induce IRF7 expression in
pHMs. Because the protein synthesis of both type I IFN and TNF
requires that IRF3/IRF7 be activated first, the direct binding of
virally activated IRF3 and IRF7 to the ISRE and IRFE in the
IRF7 promoter thus provides a rapid shortcut to trigger IRF7
transcription, whereby an initial weak signal serves as the positive
feedforward/feedback platform for a strong IRF7 expression at the
later times through robust secondary response pathways of IFN-
STAT1 and TNF-NF-kB.
In summary, our study shows that RIG-I sensing of a DNA
poxvirus infection in pHMs is critically linked to co-regulated TNF
and type I IFN responses that control viral tropism in primary
human cells in general. These data indicate that cytoplasmic RNA
sensors may play a more important role than previously envisaged
in triggering the innate antiviral cellular defenses against DNA
virus infections in human cells.
Materials and Methods
Human fibroblasts, macrophages and lymphocytes
Primary human skin fibroblasts CCD-922Sk (kindly provided
by Dr. Scot Roberts) were maintained in MEM with 10% FBS,
penicillin (100 u/ml) and streptomycin (100 mg/ml). To prepare
pHMs and primary human lymphocytes, human peripheral blood
mononuclear cells were first obtained by density gradient
centrifugation over HISTOPAQUE-1077 (Sigma) according to
the product instruction. Subsequently, the isolated peripheral
blood mononuclear cells were suspended in RPMI 1640
supplemented with 5% FBS, penicillin (100 u/ml) and streptomy-
cin (100 mg/ml) and were allowed to adhere to plastic plates for
1 h. The adherent monocytes were then separated from the
nonadherent lymphocytes by repeated washing with plain
medium. The monocyte-depleted nonadherent leukocyte fractions
were collected as the primary human lymphocytes for MV
infection experiments whereas the adherent mononcytes were
cultured in RPMI 1640 supplemented with 10% autologous
human serum for 7 days to allow differentiation into macrophages
as described previously [54].
MV and recombinant MV-hTNF
MV (Lausanne strain) with lacZ gene inserted at an innocuous
intergenic site under the control of a late viral promoter was
described previously [55]. UV-inactivated MV was prepared with
a Stratagene Stratalinker. To construct MV-hTNF, using vMyxlac
as the parental virus, we first conducted PCR synthesis of flanking
sequences for homologous recombination. The left flanking
sequence (FL) for insertion into MV ORF M131R, a nonessential
gene for MV replication, was synthesized with primer pair:
FLF_KpnI: GGTACCATACGACGTCGTACGCGAATCTG
GCA and FLR_MCS (multi-cloning site): AAGATCTAAGTC-
GACCCCGGGTAATGAA TTCTACGTAGCGGCCGCAAGCTAGCT-
CTTTATTAAACTCGTAATAGCGAGGA. The right flanking
sequence (FR) was made similarly with the primer pair:
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CA and FRF_MCS: AGCTAGCTTGCGGCCGCTACGTAGAATT-
CATTACCCGGGGTCGACTTAGATCTAACCGGTGATCGATCC-
ATTATAGGA. Note that the above-italicized letters indicate MCS.
T h e n ,t h eF La n dF RP C Rp r o d u c t sw e r em i x e da n dl i g a t e dw i t ha
second round PCR using the primer pair FLF_KpnI and FRR_SacI.
The flanking sequence containing the MCS was cloned into
pBluescriptKS+ between KpnI and SacI, and the sequence fidelity
was confirmed. The MCS contains RE sites: NheI, NotI, EcoRI,
SmaI, SalI, and BglII. Next, the gpt gene driven by vaccinia virus
early/late promoter p7.5 was inserted into the BglII site and EGFP
driven by a synthetic poxvirus early/late promoter [56] or EGFP and
human TNF, each controlled independently but in the opposite
directions by synthetic poxvirus early/late promoters, were inserted
between NheI and SmaI sites. Standard protocols for making
recombination poxviruses were used [57]. The titration of MV-
hTNF progeny virus was conducted on RK-13 using the standard
plaque assay as described [55]. For confirmation of TNF expression
by MV-hTNF, the whole cell lysates and supernatants from the RK-
13 cells infected by either control MV or MV-hTNF were rendered
for immunoblotting analysis using an anti-human TNF antibody.
Virus infection, X-gal staining, b-gal and viral yield assays
MV was used at an MOI of 0.0l for X-gal staining and b-gal
assay and at an MOI of 1.0 for RT-PCR, immunoblotting, ELISA
and ChIP experiments. X-gal staining with 5-bromo-4-chloro-3-
indolyl-b-D-galactopyranoside (Sigma) was performed to visualize
MV blue foci 48 h after infection as described [3]. Microscopic
images of X-gal staining were taken with a Leica DMIRE2
microscope. MV b-gal assay was performed as previously
described [58] with o-nitrophenyl-b-D-galactopyranoside (Sigma)
48 h after infection. The b-gal activity was normalized as optical
density at 420 nm per milligram of total cellular protein. For viral
yield assays at 48 h after infection, titers of EMCV infection
samples were determined on BHK cells [59] while MV titers were
determined on BGMK cells [55] in terms of plaque-forming units
per ml (pfu/ml) using the standard plaque assay.
Cytokine treatments, primary antibodies,
immunoblotting, ELISA and neutralization experiments
Recombinant human IFN-b and TNF were from PBL
Biomedical Laboratories and Biosource International, respectively.
IFN-b was used at 150 units/ml while TNF was used at 10 ng/ml.
Two cytokines were either added alone or together to the media
when the infection with MV or EMCV was started and
maintained throughout the entire treatment period. The primary
antibodies were obtained from the following suppliers: anti-IRF3,
anti-IRF7, anti-NF-kB p65 and anti-USF2 antibodies, Santa Cruz
Biotechnology; anti-human TNF and anti-human IFN-a/b
antibodies, Biosource International; anti-b-actin antibody, Sigma;
anti-STAT1 antibody, Transduction Laboratories. For immuno-
blotting, whole cell extracts were prepared at each specified time
after various treatments as previously described [3]. The
preparation of nuclear extracts was done according to the
published procedures [60]. The extracted proteins were resolved
on 7.5–12% SDS-PAGE and transferred to Hybond-C nitrocel-
lulose (Amersham Pharmacia Biotech). Immunoblotting was
performed with respective primary antibodies, and bands were
visualized with secondary HRP-conjugated antibodies and ECL
system (NEN Life Science Products). To quantitate TNF and IFN-
b, the supernatants from MV-infected cell cultures were collected
at various time points as specified after treatments and subjected to
analysis by standard sandwich ELISA as described [61]. For the
neutralization of TNF or IFN-a/b, or both TNF and IFN-a/b,
anti-human TNF antibody (20 mg/ml), or anti-human IFN-a/b
antibodies (each at 1,000 neutralization units/ml), or both anti-
human TNF and anti-human IFN-a/b antibodies were added,
respectively, to the medium 2 h prior to MV infection of pHMs as
indicated and kept throughout the entire infection period.
Transfection of siRNAs and poly(I:C)
The siRNA oligonucleotides targeting human RIG-I (NM_
014314), MDA5 (NM_022168), MAVS (VISA, NM_020746),
IRF3 (NM_001571) and IRF7 (NM_001572) as well as control
siRNA siCONTROL #1 were obtained from DHARMACON.
The two individual pairs of RIG-I siRNA sequences are as follows:
RIG-I siRNA-1: sense, CAGAAGAUCUUGAGGAUAAUU,
antisense, 59-P.UUAUCCUCAAGAUCUUCUGUU), and RIG-
I siRNA-2: sense, GCACAGAAGUGUAUAUUGGUU, anti-
sense, 59-P.CCAAUAUACACUUCUGUGCUU. Human NF-kB
p65 and STAT1 siRNAs were obtained from Cell Signaling
Technology. siRNAs were transfected into pHMs using HiPerFect
Transfection Reagent (Qiagen) according to the manufacturer’s
specifications. At 48 or 72 h after the transfection of various siRNAs
as indicated, the cells were used for further experiments. Synthetic
dsRNA polyinosinic-polycytidylic (poly(I:C)) was from Sigma. For
transfection, cells were incubated for various times as indicated with
1.5 mg/ml of poly(I:C) complexed with Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
Immunofluorescence microscopy
For immunofluorescent staining, pHMs were grown on cover-
slips. After infection with MV for the indicated times, the infected
cells were fixed in cold methanol for 10 min, washed in PBS and
blocked in 5% normal goat serum for 50 min. A rabbit anti-IRF3
antibody was then applied at room temperature for 1 h followed by
a 45-minsecondary detection withTexas Red-conjugated goat anti-
rabbit IgG. Thereafter, the nuclear DNA of the immunolabeled
cells were counterstained with DAPI (49,6-diamidino-2-phenylin-
dole, dihydrochloride, Molecular Probes) according to the product
specification. The secondary antibody conjugate was from Jackson
ImmunoResearch Laboratories. The fluorescence images were
taken with a Leica DMIRE2 microscope.
RT-PCR and chromatin immunoprecipitation assay
After various treatments as indicated, total RNA was isolated
using a RNeasy kit (Qiagen). Reverse transcription was performed
using Superscript reverse transcriptase (Invitrogen). RT-PCR
conditions and primer sequences for human TNF and GAPDH
[62], IFN-b [63], RIG-I, MDA5 and MAVS [64] were described.
ChIP assay was conducted as described previously [43]. Briefly,
pHMs were infected with MV for 12 h and then subjected to
cross-linking by formaldehyde. Immunoprecipitation was per-
formed with the specific antibodies or a control antibody (rabbit
IgG) as indicated. After reversion of the protein-DNA cross-links
in the immunopreciptitates, the purified DNA was analyzed by
PCR for the sequences that contain ISRE and IRFE in the
endogenous IRF7 promoter. PCR conditions and the specific
primers for IRF7 ISRE and IRFE were described [43].
Supporting Information
Figure S1 Confirmation of insertion and expression of human
TNF gene in MV genome. (A) Control MV DNA or recombinant
MV-hTNF DNA was extracted and analyzed with PCR pairs as
specified in Materials and Methods. Lanes 1 and 2: control MV.
Lanes 3 and 4: MV-hTNF. (B) RK-13 cells were infected by either
control MV or MV-hTNF as indicated for 24 h. The whole cell
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immunoblotting analysis using an anti-human TNF antibody.
Found at: doi:10.1371/journal.ppat.1000099.s001 (0.90 MB TIF)
Figure S2 Two pairs of RIG-I siRNA oligos share similar
silencing phenotypes in primary human macrophages. (A) pHMs
were transfected with control siRNA or RIG-I siRNA-1 or RIG-I
siRNA-2 as indicated (top panel). The cells were analyzed 48 h
later by RT-PCR for RIG-I mRNA levels. GAPDH was used as
control. (B, C) pHMs or various siRNA pHMs as indicated were
mock-infected or infected with MV for 24 h and the accumulation
of TNF and IFN-b in the culture supernatants was assessed by
ELISA. Data in (B) and (C) represent mean +/2 SD.
Found at: doi:10.1371/journal.ppat.1000099.s002 (0.77 MB TIF)
Figure S3 RIG-I siRNA transfection does not activate nonspe-
cific type I IFN response in pHMs. (A) pHMs were mock
transfected or transfected with poly(I:C) or with RIG-I siRNA-1 or
RIG-I siRNA-2 for 24 h. IFN-b accumulation in the culture
supernatants was assessed by ELISA. Data represent mean +/2
SD. (B) pHMs were mock transfected or transfected with poly(I:C)
or with RIG-I siRNA-1 or RIG-I siRNA-2 for 12 h. Total RNA
was analyzed by RT-PCR for induction of IFN-b mRNA.
GAPDH was used as control.
Found at: doi:10.1371/journal.ppat.1000099.s003 (0.70 MB TIF)
Acknowledgments
We thank S. Roberts for CCD-922Sk cells, R. Dowling and N. Sonenberg
for EMCV and J. Hiscott for IRF3 regents, which helped in the
development of this project. We are grateful to I. Moniz for her
administrative assistance at the Robarts Research Institute.
Author Contributions
Conceived of the project: FW GM. Performed the experiments: FW XG JB
QS EB MM MR SW TI JC. Analyzed the data: FW XG JB QS EB MM
MR SW TI JC GM. Wrote the paper: FW GD GM. Designed the
experiments: FW XG JB QS EB MM MR SW TI JC GM.
References
1. Fenner F, Ratcliffe FN (1965) Myxomatosis. Cambridge, UK: Cambridge
University Press.
2. Kerr P, McFadden G (2002) Immune responses to myxoma virus. Viral
Immunol 15: 229–246.
3. Wang F, Ma Y, Barrett JW, Gao X, Loh J, et al. (2004) Disruption of Erk-
dependent type I interferon induction breaks the myxoma virus species barrier.
Nat Immunol 5: 1266–1274.
4. Condit RC (2001) Principles of Virology. In: Knipe DM, Howley PM, eds (2001)
Fields Virology. Fourth ed. Philadelphia: Lippincott Williams & Wilkins. pp
19–51.
5. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate
immunity. Cell 124: 783–801.
6. Janeway CA Jr., Medzhitov R (2002) Innate immune recognition. Annu Rev
Immunol 20: 197–216.
7. Kawai T, Akira S (2006) TLR signaling. Cell Death Differ 13: 816–825.
8. Jacobs BL, Langland JO (1996) When two strands are better than one: the
mediators and modulators of the cellular responses to double-stranded RNA.
Virology 219: 339–349.
9. Yoneyama M, Fujita T (2007) Function of RIG-I-like receptors in antiviral
innate immunity. J Biol Chem 282: 15315–15318.
10. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, et al. (2006) 59-Triphosphate
RNA is the ligand for RIG-I. Science 314: 994–997.
11. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, et al. (2006) RIG-I-
mediated antiviral responses to single-stranded RNA bearing 59-phosphates.
Science 314: 997–1001.
12. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, et al. (2004)
The RNA helicase RIG-I has an essential function in double-stranded RNA-
induced innate antiviral responses. Nat Immunol 5: 730–737.
13. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. (2006)
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA
viruses. Nature 441: 101–105.
14. Johnson CL, Gale M Jr. (2006) CARD games between virus and host get a new
player. Trends Immunol 27: 1–4.
15. Mogensen TH, Paludan SR (2001) Molecular pathways in virus-induced
cytokine production. Microbiol Mol Biol Rev 65: 131–150.
16. Benedict CA (2003) Viruses and the TNF-related cytokines, an evolving battle.
Cytokine Growth Factor Rev 14: 349–357.
17. Herbein G, O’Brien WA (2000) Tumor necrosis factor (TNF)-alpha and TNF
receptors in viral pathogenesis. Proc Soc Exp Biol Med 223: 241–257.
18. Stetson DB, Medzhitov R (2006) Type I interferons in host defense. Immunity
25: 373–381.
19. Hiscott J, Nguyen TL, Arguello M, Nakhaei P, Paz S (2006) Manipulation of the
nuclear factor-kappaB pathway and the innate immune response by viruses.
Oncogene 25: 6844–6867.
20. Lun X, Yang W, Alain T, Shi ZQ, Muzik H, et al. (2005) Myxoma virus is a
novel oncolytic virus with significant antitumor activity against experimental
human gliomas. Cancer Res 65: 9982–9990.
21. Lun XQ, Zhou H, Alain T, Sun B, Wang L, et al. (2007) Targeting human
medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by
rapamycin. Cancer Res 67: 8818–8827.
22. Wu Y, Lun X, Zhou H, Wang L, Sun B, et al. (2008) Oncolytic efficacy of
recombinant vesicular stomatitis virus and myxoma virus in experimental
models of rhabdoid tumors. Clin Cancer Res 14: 1218–1227.
23. Samuel CE (2001) Antiviral actions of interferons. Clin Microbiol Rev 14:
778–809.
24. Wong GHW, Kamb A, Goeddel DV (1992) Antiviral properties of TNF. In:
Beutler B, ed (1992) Tumor Necrosis Factor. New York: Raven Press. pp
371–381.
25. Tracey KJ, Cerami A (1993) Tumor necrosis factor, other cytokines and disease.
Annu Rev Cell Biol 9: 317–343.
26. Falvo JV, Uglialoro AM, Brinkman BM, Merika M, Parekh BS, et al. (2000)
Stimulus-specific assembly of enhancer complexes on the tumor necrosis factor
alpha gene promoter. Mol Cell Biol 20: 2239–2247.
27. Najarro P, Traktman P, Lewis JA (2001) Vaccinia virus blocks gamma interferon
signal transduction: viral VH1 phosphatase reverses Stat1 activation. J Virol 75:
3185–3196.
28. Nakamichi I, Habtezion A, Zhong B, Contag CH, Butcher EC, et al. (2005)
Hemin-activated macrophages home to the pancreas and protect from acute
pancreatitis via heme oxygenase-1 induction. J Clin Invest 115: 3007–3014.
29. Okazawa H, Motegi S, Ohyama N, Ohnishi H, Tomizawa T, et al. (2005)
Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1
system. J Immunol 174: 2004–2011.
30. Reynolds A, Anderson EM, Vermeulen A, Fedorov Y, Robinson K, et al. (2006)
Induction of the interferon response by siRNA is cell type- and duplex length-
dependent. Rna 12: 988–993.
31. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR (2003) Activation
of the interferon system by short-interfering RNAs. Nat Cell Biol 5: 834–839.
32. Seth RB, Sun L, Chen ZJ (2006) Antiviral innate immunity pathways. Cell Res
16: 141–147.
33. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, et al. (2005) IPS-1, an
adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat
Immunol 6: 981–988.
34. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, et al. (2005) Cardif
is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis
C virus. Nature 437: 1167–1172.
35. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, et al. (2005) VISA is an adapter
protein required for virus-triggered IFN-beta signaling. Mol Cell 19: 727–740.
36. Honda K, Taniguchi T (2006) IRFs: master regulators of signalling by Toll-like
receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6:
644–658.
37. Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, et al. (2000) Distinct and
essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for
IFN-alpha/beta gene induction. Immunity 13: 539–548.
38. Covert MW, Leung TH, Gaston JE, Baltimore D (2005) Achieving stability of
lipopolysaccharide-induced NF-kappaB activation. Science 309: 1854–1857.
39. Doyle SL, O’Neill LA (2006) Toll-like receptors: from the discovery of
NFkappaB to new insights into transcriptional regulations in innate immunity.
Biochem Pharmacol 72: 1102–1113.
40. Duguay D, Mercier F, Stagg J, Martineau D, Bramson J, et al. (2002) In vivo
interferon regulatory factor 3 tumor suppressor activity in B16 melanoma
tumors. Cancer Res 62: 5148–5152.
41. Nociari M, Ocheretina O, Schoggins JW, Falck-Pedersen E (2007) Sensing
infection by adenovirus: Toll-like receptor-independent viral DNA recognition
signals activation of the interferon regulatory factor 3 master regulator. J Virol
81: 4145–4157.
42. Servant MJ, Tenoever B, Lin R (2002) Overlapping and distinct mechanisms
regulating IRF-3 and IRF-7 function. J Interferon Cytokine Res 22: 49–58.
43. Ning S, Huye LE, Pagano JS (2005) Regulation of the transcriptional activity of
the IRF7 promoter by a pathway independent of interferon signaling. J Biol
Chem 280: 12262–12270.
RIG-I Mediates MV-Induced TNF/IFN
PLoS Pathogens | www.plospathogens.org 12 July 2008 | Volume 4 | Issue 7 | e100009944. Lu R, Moore PA, Pitha PM (2002) Stimulation of IRF-7 gene expression by
tumor necrosis factor alpha: requirement for NFkappa B transcription factor and
gene accessibility. J Biol Chem 277: 16592–16598.
45. Marie I, Durbin JE, Levy DE (1998) Differential viral induction of distinct
interferon-alpha genes by positive feedback through interferon regulatory factor-
7. Embo J 17: 6660–6669.
46. Kumar H, Kawai T, Kato H, Sato S, Takahashi K, et al. (2006) Essential role of
IPS-1 in innate immune responses against RNA viruses. J Exp Med 203:
1795–1803.
47. Cheng G, Zhong J, Chung J, Chisari FV (2007) Double-stranded DNA and
double-stranded RNA induce a common antiviral signaling pathway in human
cells. Proc Natl Acad Sci U S A 104: 9035–9040.
48. Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, et al. (2006) Essential role of
mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and
encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A 103: 8459–8464.
49. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, et al. (2007) DAI (DLM-
1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response.
Nature 448: 501–505.
50. Wang Z, Choi MK, Ban T, Yanai H, Negishi H, et al. (2008) Regulation of
innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing
molecules. Proc Natl Acad Sci U S A 105: 5477–5482.
51. Johnston JB, Nazarian SH, Natale R, McFadden G (2005) Myxoma virus
infection of primary human fibroblasts varies with cellular age and is regulated
by host interferon responses. Virology 332: 235–248.
52. Baud V, Karin M (2001) Signal transduction by tumor necrosis factor and its
relatives. Trends Cell Biol 11: 372–377.
53. Kang YJ, Kim SO, Shimada S, Otsuka M, Seit-Nebi A, et al. (2007) Cell surface
4-1BBL mediates sequential signaling pathways ‘downstream’ of TLR and is
required for sustained TNF production in macrophages. Nat Immunol 8:
601–609.
54. Gupta M, Mahanty S, Ahmed R, Rollin PE (2001) Monocyte-derived human
macrophages and peripheral blood mononuclear cells infected with ebola virus
secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in
vitro. Virology 284: 20–25.
55. Mossman K, Nation P, Macen J, Garbutt M, Lucas A, et al. (1996) Myxoma
virus M-T7, a secreted homolog of the interferon-gamma receptor, is a critical
virulence factor for the development of myxomatosis in European rabbits.
Virology 215: 17–30.
56. Chakrabarti S, Sisler JR, Moss B (1997) Compact, synthetic, vaccinia virus
early/late promoter for protein expression. Biotechniques 23: 1094–1097.
57. Falkner FG, Moss B (1988) Escherichia coli gpt gene provides dominant
selection for vaccinia virus open reading frame expression vectors. J Virol 62:
1849–1854.
58. Li Y, Hall RL, Moyer RW (1997) Transient, nonlethal expression of genes in
vertebrate cells by recombinant entomopoxviruses. J Virol 71: 9557–9562.
59. Wong GH, Goeddel DV (1986) Tumour necrosis factors alpha and beta inhibit
virus replication and synergize with interferons. Nature 323: 819–822.
60. Perry AK, Chow EK, Goodnough JB, Yeh WC, Cheng G (2004) Differential
requirement for TANK-binding kinase-1 in type I interferon responses to toll-
like receptor activation and viral infection. J Exp Med 199: 1651–1658.
61. Lokensgard JR, Hu S, Sheng W, vanOijen M, Cox D, et al. (2001) Robust
expression of TNF-alpha, IL-1beta, RANTES, and IP-10 by human microglial
cells during nonproductive infection with herpes simplex virus. J Neurovirol 7:
208–219.
62. Stewart MJ, Kulkarni SB, Meusel TR, Imani F (2006) c-Jun N-terminal kinase
negatively regulates dsRNA and RSV induction of tumor necrosis factor- alpha
transcription in human epithelial cells. J Interferon Cytokine Res 26: 521–533.
63. Benedict CA, Banks TA, Senderowicz L, Ko M, Britt WJ, et al. (2001)
Lymphotoxins and cytomegalovirus cooperatively induce interferon-beta,
establishing host-virus detente. Immunity 15: 617–626.
64. Sasai M, Shingai M, Funami K, Yoneyama M, Fujita T, et al. (2006) NAK-
associated protein 1 participates in both the TLR3 and the cytoplasmic
pathways in type I IFN induction. J Immunol 177: 8676–8683.
RIG-I Mediates MV-Induced TNF/IFN
PLoS Pathogens | www.plospathogens.org 13 July 2008 | Volume 4 | Issue 7 | e1000099